<DOC>
	<DOCNO>NCT00181545</DOCNO>
	<brief_summary>Radiotherapy treatment choice inoperable lung cancer . Research show local control rate low radiation often cause pneumonitis and/or esophagitis . To predict lung damage mean lung dose calculate . This allow u give high total dose tumor improve local control rate . Study hypothesis : It safe administer radiation dose high possible tumor , take account mean lung dose , calculate treatment planning system .</brief_summary>
	<brief_title>Safety Study Individualised Radiation Dose Determination Lung Cancer Patients .</brief_title>
	<detailed_description>Radiotherapy treatment choice inoperable lung cancer . Research show survival rate well local control rate low . If chemotherapy treatment add lead slightly well outcome . The radiotherapy treatment often cause pneumonitis and/or esophagitis . So damage normal tissue restrict radiation dose administer . However , several study show high dos lead well local control . Furthermore evident radiotherapy treatment give short time , preferably treatment time exceed 32 day . To avoid high toxicity normal tissue spar , increase local control rate tumor dose must high possible . This dilemma solve use sophisticated treatment plan technique combination biologically superior treatment schedule . This schedule consist deliver radiation dose twice day instead , thus keep overall treatment time low possible . For whole patient population , mean lung dose great extend predict probability develop radiation pneumonitis post-radiotherapy lung function . A logical next step determine dose radiotherapy individualised calculation maximum tolerate dose , defined mean lung dose spinal cord dose . The objective trial investigate whether individualised radiation dose calculation base mean lung dose constraint spinal cord , combination overall treatment time le 32 day , irradiate primary tumor PET scan positive mediastinal area safe .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically proven nonsmall cell lung cancer UICC stage IIII WHO performance status 02 Less 10 % weight loss last 6 month In case previous chemotherapy , radiotherapy start minimum 21 day last chemotherapy course Reasonable lung function : FEV1 Â³ 60 % predict value No recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) No active peptic oesophagitis Life expectancy 6 month Measurable cancer Willing able comply study prescription 18 year old Not pregnant willing take adequate contraceptive measure study Have give write informed consent patient registration No previous radiotherapy chest Not nonsmall cell histology , e.g . mesothelioma , lymphoma Mixed pathology , e.g . nonsmall cell plus small cell cancer Malignant pleural pericardial effusion Concurrent chemotherapy radiation History prior chest radiotherapy Recent ( &lt; 3 month ) myocardial infarction Uncontrolled infectious disease Distant metastases ( stage IV ) Patients active peptic oesophagitis last year . Less 18 year old Pregnant willing take adequate contraceptive measure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Non-small cell lung carcinoma</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>mean lung dose</keyword>
</DOC>